Yıl: 2009 Cilt: 57 Sayı: 1 Sayfa Aralığı: 48 - 55 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Community acquired pneumonia and direct hospital cost

Öz:
Türkiye’de toplum kökenli pnömoni (TKP)’nin direkt ve indirekt maliyeti ile ilgili veriler yetersizdir. Bu çalışmada, TKP olgularının klinik, laboratuvar ve radyolojik özelliklerini, direkt hastane maliyetini ve buna etki eden faktörleri belirlemek amaçlanmıştır. Olguların gruplanması ve maliyetin incelenmesinde pnömoni ağırlık skoru (PSI) ve Türk Toraks Derneği TKP Rehberi kullanılmıştır. Yaş ortalaması 70.9 olan 114 olgunun verileri retrospektif olarak incelendi. Ortalama hastanede yatış süresi 11.0 ± 6.6 gündü. Türk Toraks Derneği TKP rehberine göre grup IIIb’de yer alan ve PSI skor ortalaması 102.7 olan 3 olgu ölümle sonuçlandı. Ortalama ilaç maliyeti 484.59 Euro, radyoloji maliyeti 65.38 Euro, laboratuvar maliyeti 329.38 Euro ve toplam maliyet 1630.77 Euro idi. Grup IIIb’de yer alan olgularda ilaç maliyeti ve toplam maliyet diğer gruplara göre yüksekti. Radyolojik, laboratuvar ve toplam maliyet açısından başlangıç tedavisi rehbere uygun olan ve olmayan olgular arasında farklılık saptanmadı (p> 0.05). Cinsiyet ve ileri yaşın (≥ 65 yaş) toplam maliyet üzerine etkisi saptanmadı (p> 0.05). Ek hastalık varlığının toplam maliyeti artırdığı belirlendi (p= 0.003). PSI skorlamasına göre toplam maliyet düşük risk grubunda 1274.60 Euro, yüksek risk grubunda 1929.49 Euro idi. TKP’ye bağlı hastane mortalitesi %2.6 idi.
Anahtar Kelime: Pnömoni Yatış süresi Toplum kökenli enfeksiyonlar Masraflar ve maliyet analizi

Konular: Solunum Sistemi Kulak, Burun, Boğaz

Toplum kökenli pnömoni ve hastane maliyeti

Öz:
In Turkey, there is inadequate data about the direct or indirect cost of community acquired pneumonia (CAP). This study aims to identify the clinical, laboratory, and radiological properties, direct hospital costs of CAP, and the factors that affect these costs. Grouping of the subjects and cost analysis were evaluated in accordance with Pneumonia Severity Index (PSI) and ‘Turkish Thoracic Society (TTS) CAP Guideline’. 114 cases with an average age of 70.9 were analyzed retrospectively. Average hospital stay was 11.0 ± 6.6 days. Three of the cases that appeared to be in group IIIb in accordance with TTS CAP Guideline, and that had a PSI score of 102.7 died. Average costs of medicine was 484.59 Euro, radiology costs were 65.38 Euro, laboratory costs were 329.38 Euro and the total cost was 1630.77 Euro. In group IIIb cases, costs of medicine and the total costs were higher than other groups. Radiological, laboratory and the total costs were not determined to be different among cases that did or did not conform to initial treatment guidelines (p> 0.05). There were no effect of gender and advanced age (≥ 65 years) on total cost (p> 0.05). Existence of a comorbid disease was detected to have increased the total cost (p= 0.003). Total costs according to PSI scoring were 1274.60 Euro in low-risk group, and 1929.49 Euro in high-risk group (p= 0.04). Hospital mortality due to CAP was 2.6%.
Anahtar Kelime: Costs and Cost Analysis Pneumonia Length of Stay Community-Acquired Infections

Konular: Solunum Sistemi Kulak, Burun, Boğaz
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005; 118: 29-38.
  • 2. Marras TK, Chan CK. Use of guidelines in treating community- acquired pneumonia. Chest 1998; 113: 1689-94 .
  • 3. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community- acquired pneumonia from the hospital perspective. Chest 2005; 128: 2238-46.
  • 4. Wasserfallen JB, Erard V, Cometta A, Calandra T, Lamy O. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. Eur Respir J 2004; 24: 644-48.
  • 5. S. Merchant, MBA, CD. Mullins, YCT. Shih. Factors associated with hospitalization costs for patients with community- acquired pneumonia. Clin Ther 2003; 25: 593-610.
  • 6. Arnold FW, Ramirez JA, McDonald LC, Xia EL, Hospitalization for community-acquired pneumonia: The pneumonia severity index vs clinical judgment. Chest 2003; 124: 121-4.
  • 7. Ston RA, Mor MK, Lave JR, Hough LJ, Fine MJ. Implementation of an inpatient management and discharge strategy for patients with community-acquired pneumonia. Am J Manag Care 2005; 11: 491-9.
  • 8. Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997; 52: 17-21.
  • 9. Guest JF, Morris A. Community-acquired pneumonia: The annual cost to the the National Health Service in the United Kingdom. Eur Respir J 1997; 10: 1530-34.
  • 10. Brown PD. Adherence to guidelines for community-acquired pneumonia does it decrease cost of care? Pharmacoeconomics 2004; 22: 413-20.
  • 11. Gregory PS, David BM, James H, Jerome W. A.Cost minimization analysis compairing azithromycin based and levofloksasin based protocols for the treatment of patients hospitalized with community acquired pneumonia. Chest 2005; 128: 3246-54.
  • 12. DW. Alves, MT. Kenned. Community-acquired pneumonia in casualty: Etiology, clinical features, diagnosis, and management (or a look at the “new” in pneumonia since 2002) .Curr Opin Pulm Med 2004; 10: 166-70.
  • 13. Özlü T, Bülbül Y, Özsu S . Ulusal verilerle toplum kökenli pnömoniler. Tuberk Toraks 2007; 55: 191-212.
  • 14. Kolsuz M, Uçgun Y, Metintaş M ve ark. Hastaneye yatarak veya yoğun bakımda tedavi görmesi gereken toplum kökenli pnömonilerde hastanede yatış süresini etkileyen faktörler ve maliyet. Toraks Derneği Yıllık Kongresi 2000. SS 022.
  • 15. Yarkın T, Yazıcıoğlu Ö, Yaldız E ve ark. Hastanede yatırılarak tedavi edilen toplum kökenli pnömoni olgularında antibiyotik maliyeti. Toraks Dergisi 2002; 3(Ek 1): 120(SS 467).
  • 16. Brown RB, Iannini P, Gross P, Kunkel M. Impact of Initial Antibiotic Choice on Clinical Outcomes in Community- Acquired Pneumonia Analysis of a Hospital Claims-Made Database.
APA doruk s, Tertemiz K, KÖMÜS N, Uçan E, KILINC O, Sevinc C (2009). Community acquired pneumonia and direct hospital cost. , 48 - 55.
Chicago doruk sibel,Tertemiz Kemal Can,KÖMÜS Nuray,Uçan Eyüp Sabri,KILINC OGUZ,Sevinc Can Community acquired pneumonia and direct hospital cost. (2009): 48 - 55.
MLA doruk sibel,Tertemiz Kemal Can,KÖMÜS Nuray,Uçan Eyüp Sabri,KILINC OGUZ,Sevinc Can Community acquired pneumonia and direct hospital cost. , 2009, ss.48 - 55.
AMA doruk s,Tertemiz K,KÖMÜS N,Uçan E,KILINC O,Sevinc C Community acquired pneumonia and direct hospital cost. . 2009; 48 - 55.
Vancouver doruk s,Tertemiz K,KÖMÜS N,Uçan E,KILINC O,Sevinc C Community acquired pneumonia and direct hospital cost. . 2009; 48 - 55.
IEEE doruk s,Tertemiz K,KÖMÜS N,Uçan E,KILINC O,Sevinc C "Community acquired pneumonia and direct hospital cost." , ss.48 - 55, 2009.
ISNAD doruk, sibel vd. "Community acquired pneumonia and direct hospital cost". (2009), 48-55.
APA doruk s, Tertemiz K, KÖMÜS N, Uçan E, KILINC O, Sevinc C (2009). Community acquired pneumonia and direct hospital cost. Tüberküloz ve Toraks, 57(1), 48 - 55.
Chicago doruk sibel,Tertemiz Kemal Can,KÖMÜS Nuray,Uçan Eyüp Sabri,KILINC OGUZ,Sevinc Can Community acquired pneumonia and direct hospital cost. Tüberküloz ve Toraks 57, no.1 (2009): 48 - 55.
MLA doruk sibel,Tertemiz Kemal Can,KÖMÜS Nuray,Uçan Eyüp Sabri,KILINC OGUZ,Sevinc Can Community acquired pneumonia and direct hospital cost. Tüberküloz ve Toraks, vol.57, no.1, 2009, ss.48 - 55.
AMA doruk s,Tertemiz K,KÖMÜS N,Uçan E,KILINC O,Sevinc C Community acquired pneumonia and direct hospital cost. Tüberküloz ve Toraks. 2009; 57(1): 48 - 55.
Vancouver doruk s,Tertemiz K,KÖMÜS N,Uçan E,KILINC O,Sevinc C Community acquired pneumonia and direct hospital cost. Tüberküloz ve Toraks. 2009; 57(1): 48 - 55.
IEEE doruk s,Tertemiz K,KÖMÜS N,Uçan E,KILINC O,Sevinc C "Community acquired pneumonia and direct hospital cost." Tüberküloz ve Toraks, 57, ss.48 - 55, 2009.
ISNAD doruk, sibel vd. "Community acquired pneumonia and direct hospital cost". Tüberküloz ve Toraks 57/1 (2009), 48-55.